Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

Immune Based Strategies for Myeloma: Combining Antibodies for Optimal Outcomes


 
Description:
The treatment landscape for multiple myeloma (MM) is evolving rapidly, and pharmacists need to be aware of an increasing number of therapeutic options in the frontline and salvage settings. The ability of immunomodulatory drugs and proteasome inhibitors to achieve deep and durable remission rates in MM has yielded meaningful benefits for patients, and further significant advancements are anticipated. Several new molecularly targeted and immunotherapeutic agents are currently under clinical exploration, many in phase 3 trials. These agents include inhibitors of proliferation and apoptosis, inhibitors of protein homeostasis, next-generation oral proteasome inhibitors, and monoclonal antibodies that target myeloma cell surface proteins. However, combined with the heterogeneity of MM and the diversity of the patient population, the fast-evolving MM armamentarium is making patient care increasingly complex. This program will equip pharmacists with the most current information on the strategies for optimizing current and emerging therapies for the treatment of MM. 

Learning Objectives:

  1. Distinguish between the indicated uses, mechanisms of action, depth and duration of clinical responses, and safety of current and emerging immunotherapeutic targeted agents.
  2. Outline a treatment plan for newly diagnosed patients to achieve the deepest and most durable response while balancing the risk for adverse events.
  3. Outline a treatment plan for patients who have relapsed from, or are refractory to, their treatment.
Activity Number:
0280-0000-16-088-H01-P

This recorded activity is a based on a live program that was offered on October 15, 2016 in Burlington, MA.  
Participants who received credit for the live program should not claim credit for this web based presentation.
 
System Requirements for Participants:
Operating system:  Windows XP, Vista or 7  MAC OS X  Latest Version of Adobe Reader
Browser Internet Explorer 8.0 or above  Google Chrome 16.0 or above  Firefox 7.0 or above  Safari 5.0 or above
 

Fee

$0.00

CE Hours

1.00

CE Units

0.100

Activity Type

  • Knowledge Based

Target Audience(s)

  • Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
American Health Resources is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Requirements for CE Credit

  • Complete the pre-test
  • Review the content of this activity
  • Successfully complete the post-test with a score of 80% or higher 
  • Complete the evaluation
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation is completed.
 
Pharmacists - Be sure your profile has been updated with your NAPB e-profile # and birth date information BEFORE completing the online evaluation, or your credits will NOT be reported.

Support/Credits

Disclosures:
R. Donald Harvey, PharmD, FCCP, BCOP; Associate Professor, Hematology/Medical Oncology; Director, Phase 1 Clinical Trials Section, Winship Cancer Institute Of Emory University
Dr. Harvey has received research funding from Amgen, Bristol-Myers Squibb, Calithera, Celgene, Cleave, Novartis, Onyx and Takeda. Presenter is also on the advisory boards of Bristol-Myers Squibb and Takeda. 
 
The reviewer is Ali McBride, PharmD, MS, BCPS, BCOP Clinical Coordinator Hematology/Oncology,
The University of Arizona Cancer Center, Tucson, AZ.  
Dr. McBride does not have any relevant financial relationships with any commercial interests.
 
Support for This Activity:
This activity is supported by the Association of Community Cancer Centers (ACCC)
 
American Health Resources assesses conflict of interest with its instructors, reviewers and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are resolved by American Health Resources for fair balance and scientific objectivity.
 
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  American Health Resources does not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of American Health Resources.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

 

 

The treatment landscape for multiple myeloma (MM) is evolving rapidly, and pharmacists need to be aware of an increasing number of therapeutic options in the frontline and salvage settings. The ability of immunomodulatory drugs and proteasome inhibitors to achieve deep and durable remission rates in MM has yielded meaningful benefits for patients, and further significant advancements are anticipated. Several new molecularly targeted and immunotherapeutic agents are currently under clinical exploration, many in phase 3 trials. These agents include inhibitors of proliferation and apoptosis, inhibitors of protein homeostasis, next-generation oral proteasome inhibitors, and monoclonal antibodies that target myeloma cell surface proteins. However, combined with the heterogeneity of MM and the diversity of the patient population, the fast-evolving MM armamentarium is making patient care increasingly complex. This program will equip pharmacists with the most current information on the strategies for optimizing current and emerging therapies for the treatment of MM. 
 

Objectives

  • Distinguish between the indicated uses, mechanisms of action, depth and duration of clinical responses, and safety of current and emerging immunotherapeutic targeted agents.
  • Outline a treatment plan for newly diagnosed patients to achieve the deepest and most durable response while balancing the risk for adverse events.
  • Outline a treatment plan for patients who have relapsed from, or are refractory to, their treatment.

Speaker(s)/Author(s)

R. Donald Harvey, PharmD, FCCP, BCOP picture

R. Donald Harvey, PharmD, FCCP, BCOP
Assistant Professor, Hematology/Medical Oncology, Director, Phase 1 Clinical Trials Section, Winship Cancer Institute of Emory University


Brief Bio : R. Donald Harvey, PharmD, is Assistant Professor of Hematology and Medical Oncology and Pharmacology at the Winship Cancer Institute of Emory University. A Board Certified Oncology Pharmacist, Dr. Harvey serves as director of the Winship Cancer Institute's Phase I Clinical Trials Unit and Section and as chair of the Data and Safety Monitoring Committee. He is a Fellow of the American College of Clinical Pharmacy and a Fellow of the Hematology/Oncology Pharmacy Association.

Activity Number

0280-0000-16-088-H01-P

Release Date: Nov 29, 2016
Credit Expiration Date: Nov 29, 2018

CE Hours

1.00

Fee

$0.00